Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis [2]

Scandinavian Journal of Rheumatology

Volumn 34, Issue 5, 2005, Pages 410-411

  Iwamoto, Masahiro ^a   Homma, S ^b   Asano, Y ^b   Minota, S ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Mito Red Cross Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; TERIFLUNOMIDE;

BLOOD SAMPLING; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; JOINT LIMITATION; JOINT STIFFNESS; KIDNEY FAILURE; LETTER; MAINTENANCE DRUG DOSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL DIALYSIS;

EID: 27544439522     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740510018723     Document Type: Letter

References (4)

1. Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother 2002;36:75-7.
2. Clinical pharmacology/biopharmaceutics review, Leflunomide tablets, Arava; summary basis of approval equivalent. FDA/CDER Summary Basis of Approval. NDA: 1998;20-905.
3. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
4. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.